Ask about this productRelated genes to: NOSTRIN antibody
- Gene:
- NOSTRIN NIH gene
- Name:
- nitric oxide synthase trafficking
- Previous symbol:
- -
- Synonyms:
- MGC20702
- Chromosome:
- 2q24.3
- Locus Type:
- gene with protein product
- Date approved:
- 2003-01-06
- Date modifiied:
- 2016-10-05
Related products to: NOSTRIN antibody
Related articles to: NOSTRIN antibody
- Vasculogenic mimicry (VM) plays vital roles in tumor development that are closely relevant to patient adverse outcomes and chemoresistance. This study aimed to identify a novel VM-associated signature to forecast the prognosis and immunotherapy response of head and neck squamous cell carcinoma (HNSC) patients. - Source: PubMed
Publication date: 2026/04/30
Zhai YujiaGu XinyuHuang DiXue Miaomiao - Introduction Head and neck squamous cell carcinoma (HNSCC) is the most common cancer of the head and neck region, including the oral cavity, larynx, pharynx, nasal cavity, and paranasal sinuses. Cancer arises because of cumulative genetic and epigenetic alterations in cancer-associated genes. It is important to understand the genetic/epigenetic background of the tumors to establish molecular targeted therapies. So far, the knowledge of key genes or molecules, which are closely associated with the carcinogenesis and development of HNSCC, is insufficient for targeted therapies. On the other hand, recent advances in next-generation sequencing (NGS) have greatly contributed to cancer genome research. In this research, using RNA sequence data of HNSCC stored in The Cancer Genome Atlas (TCGA) database, we identified differentially expressed genes (DEGs), functionally enriched gene sets, and new prognostic markers or candidate therapeutic targets. This exploratory study investigated whether novel prognostic markers and candidate therapeutic targets for HNSCC could be identified from TCGA RNA-seq data. Methods The RNA sequence data were downloaded from TCGA, including 504 cases from cancer and 44 cases from corresponding normal tissue. The DEGs between cancer and normal samples were detected using the DESeq2 package in R software. Differences with | log2 fold change (FC) | > 1.0 and p-value <0.05 were considered as DEGs. Functional enrichment analyses were performed by ShinyGO 0.85 with Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. A gene set enrichment analysis (GSEA) was also performed using GSEA software. We also analyzed the top 10 up- and down-regulated genes, which were sorted by adjusted p-value, by using Kaplan-Meier analysis to assess their potential as prognostic markers. Results Using the DESeq2 package, 10,976 DEGs were detected, including 6,932 up-regulated genes and 4,044 down-regulated genes in cancer. As expected, functional enrichment analyses revealed enrichment of KEGG terms associated with cancers, including "Pathway in Cancer", "Human Papillomavirus infection", and "PI3K-Akt signaling pathway" in up-regulated genes, whereas KEGG terms enriched in down-regulated genes were mainly "Metabolic pathways". GO terms for "Cell differentiation (GOBP)" and "Extracellular region (GOCC)" were enriched both in up- and down-regulated genes, suggesting aberrant expression of genes associated with cell differentiation and remodeling of the extracellular matrix. GSEA data supported the enrichment analyses data. Kaplan-Meier analyses revealed that high expression of homeobox C6 () (p=0.048), nucleobindin 2 () (p=0.007), IL12A antisense RNA 1 () (p=0.001), calcium-binding protein 39-like ()(p=0.038) nitric oxide synthase traffickin () (p=0.024), SLC8A1 antisense RNA 1 () (p=0.016), were the significantly correlated with poorer prognosis. Conclusions Based on bioinformatical approaches, we identified significantly enriched gene sets and novel candidates for prognostic markers or therapeutic targets in HNSCC. Further investigation would aid in determining the anti-cancer effects of these candidates. - Source: PubMed
Publication date: 2025/10/14
Katase NaokiSakamoto YaeSuda HirokiMiyahara RinFujita Shuichi - Metabolic dysfunction-associated steatotic liver disease (MASLD) complications are an expanding health problem concomitant with endothelial dysfunction (ED) at early stages of the disease. This study aimed to identify the levels of a novel endothelial nitric oxide synthase (eNOS) trafficking inducer, Nostrin, in patients with MASLD compared to healthy volunteers (HV). Additionally, we investigated the association between Nostrin and endothelial dysfunction (ED) in MASLD patients. - Source: PubMed
Publication date: 2025/09/23
Vairappan BalasubramaniyanSubramani KalaivaniSudha Machavaram DeepthiVs SunithaSahoo Jayaprakash - Serum Nostrin was recently identified as novel predictor of important clinical outcomes in acute kidney injury (AKI) and has also emerged as a predictor of recovery of kidney function (ROKF) in AKI patients. ROKF is a critical factor for the transition of AKI into chronic kidney disease (CKD). Therefore the aim of the present study was to evaluate serum Nostrin levels in CKD patients. - Source: PubMed
Publication date: 2025/04/14
Latuske VivienErfurt StefanPatschan DanielHoffmeister Meike - Benign prostatic hyperplasia (BPH) is a common disease among older men characterized by non-malignant proliferation of epithelial cells and inflammation. Nitric oxide synthase traffic inducer (NOSTRIN) is a pleiotropic regulator of endothelial cell function and signaling and exerts anti-inflammatory, anti-proliferation, and modulating nuclear factor-kappa B (NF-κB) signaling effects. Its expression and function in BPH tissues and prostate epithelial cells are unknown. The study aims to investigate the expression and functions of NOSTRIN in BPH, and its possible molecular mechanism. - Source: PubMed
Publication date: 2024/09/24
Li ShoubinYu ChunhongXiao HelongXu QingleGao BoGuo LiuxiongSun ZhanxinLiu Junjiang